MichaelMillensonMD

PubMed

• 5 citations
  Patient-centered care innovations by accountable care organizations: Lessons from leaders.
  Michael L. Millenson, David B. Muhlestein, Emily M. O’Donnell, Daniel A. Northam Jones, R. Sterling Haring, Thomas Merrill, Joel S. Weissman> ;Healthcare. 2019 Dec 1
• Medicare for All's Political Reality: A Barista Planning to Marry a Movie Star.
  Michael L. Millenson> ;The Journal of Ambulatory Care Management. 2019 Jul 1
• 6 citations
  High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex
  Zheng Zhou, Alfred Rademaker, Leo I. Gordon, Ann S. LaCasce, Allison Crosby-Thompson, Ann Vanderplas, Gregory A. Abel, Maria A Rodriguez, Auayporn Nademanee, Mark S. K...> ;Journal of the National Comprehensive Cancer Network. 2016 Oct 1
• 111 citations
  Cancer-associated venous thromboembolic disease, version 1.2015: Featured updates to the NCCN Guidelines
  Michael B. Streiff, Bjorn Holmstrom, Aneel A. Ashrani, Paula L. Bockenstedt, Carolyn M. Chesney, Charles S. Eby, John Fanikos, Randolph B. Fenninger, Annemarie E. Foge...> ;Journal of the National Comprehensive Cancer Network. 2015 Sep 1
• 31 citations
  Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project.
  Bouthaina S. Dabaja, Ann Vanderplas, Allison Crosby-Thompson, Gregory A. Abel, Myron S. Czuczman, Jonathan W. Friedberg, Leo I. Gordon, Mark S. Kaminski, Joyce C. Nila...> ;Cancer. 2015 Apr 1
• 15 citations
  Frontline Bortezomib and Rituximab for the Treatment of Newly Diagnosed High Tumour Burden Indolent non-Hodgkin Lymphoma: A Multicentre Phase II Study
  Andrew M. Evens, Mitchell R. Smith, Izidore S. Lossos, Irene Helenowski, Michael Millenson, Jane N. Winter, Steve Rosen, Leo I. Gordon> ;British Journal of Haematology. 2014 Aug 1
• 585 citations
  An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
  Zheng Zhou, Laurie H. Sehn, Alfred Rademaker, Leo I. Gordon, Ann S. LaCasce, Allison Crosby-Thompson, Ann Vanderplas, Andrew D. Zelenetz, Gregory A. Abel, Maria Alma R...> ;Blood. 2014 Feb 6
• 28 citations
  Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma
  Danielle Shafer, Mitchell R. Smith, Hossein Borghaei, Michael Millenson, Tianyu Li, Samuel Litwin, Rachna Anad, Tahseen Al-Saleem> ;Leukemia Research. 2013 Oct 1
• 125 citations
  Acute myeloid leukemia, version 2.2013 featured updates to the NCCN guidelines
  Margaret R. O'Donnell, Martin S. Tallman, Camille N. Abboud, Jessica K. Altman, Frederick R. Appelbaum, Daniel A. Arber, Eyal C. Attar, Uma Borate, Steven Coutre, Lloy...> ;Journal of the National Comprehensive Cancer Network. 2013 Sep 1
• Phase II study of bevacizumab and erlotinib in treatment-naive elderly patients (older than age 65) with advanced non-small cell lung cancer (NSCLC).
  Borghaei H, Mehra R, Millenson MM, Tuttle H, Ruth K, Magdalinski AJ, Mintzer DM, Lee J, Stevenson J, Langer CJ> ;J. Clin. Oncol.. 2011-05-20
• 38 citations
  Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017.
  Hossein Borghaei, Corey J. Langer, Michael Millenson, Karen Ruth, Samuel Litwin, Holly Tuttle, Judie Sylvester Seldomridge, Marc Rovito, David M. Mintzer, Roger B. Coh...> ;Journal of Thoracic Oncology. 2008 Nov 1
• 6 citations
  Promising Survival in Patients with Recurrent Non-small Cell Lung Cancer Treated with Docetaxel and Gemcitabine in Combination as Second-Line Therapy
  Chao Hui Huang, Michael Millenson, Eric J. Sherman, Hossein Borghaei, David M. Mintzer, Roger B. Cohen, Arthur P. Staddon, Judi Seldomridge, Ocn Joseph Treat, Holly Tu...> ;Journal of Thoracic Oncology. 2008 Sep 1
• Phase II trial of cetuximab (C225) in combination with monthly carboplatin (Cb) and weekly paclitaxel (Pac) in patients with advanced NSCLC: Promising early results.
  Borghaei H, Langer CJ, Millenson M, Tuttle H, Seldomridge J, Rovito M, Mintzer D, Treat J> ;J. Clin. Oncol.. 2008-05-20
• Phase I trial of combination therapy with 90Y ibritumomab tiuxetan and gemcitabine in patients with non-Hodgkin's lymphoma.
  Borghaei H, Smith M, Millenson M, Krieger K, Rogatko A, Schilder R> ;J. Clin. Oncol.. 2006-06-20
• Join now to see all